-
公开(公告)号：JP6058264B2
公开(公告)日：2017-01-11
申请号：JP2011517153
申请日：2009-07-08
Applicant: ジェウヌロ・エスエー , GeNeuro SA
Inventor： ベルナール、コランヌ , ランク、アロイス・ベルンハルト , ペロン、エルベ , ベルトラン、ジャン−バプティスト
IPC: A61K39/395 , A61P1/18 , A61P3/10 , A61P17/06 , A61P25/00 , A61P25/08 , A61P25/18 , A61P35/00 , C07K14/15 , C07K16/10 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/02 , G01N33/53 , G01N33/569 , G01N33/574 , C12N15/09
CPC classification number: C07K16/1036 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92
-
公开(公告)号：JP2015157812A
公开(公告)日：2015-09-03
申请号：JP2015048795
申请日：2015-03-11
Applicant: ジェウヌロ・エスエー , GeNeuro SA
Inventor： コランヌ・ベルナール , アロイス・ベルンハルト・ランク , エルベ・ペロン , ジャン−バプティスト・ベルトラン
IPC: C12N15/09 , C07K14/155 , C12N1/21 , C12N5/10 , C12N1/19 , C12N1/15 , C12P21/08 , C12P21/00 , A61K39/395 , A61P25/00 , A61P25/18 , A61P25/08 , A61P35/00 , A61P17/06 , A61P1/18 , A61P3/10 , A61P43/00 , G01N33/569 , C07K16/08
CPC classification number: C07K16/1036 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92
Abstract: 【課題】多発性硬化症関連レトロウイルス(MSRV)関連疾患の診断法及び治療法の提供。 【解決手段】標的分子(アンチリガンド)であるMSRVエンベロープ(ENV)タンパク質に対する特異的なリガンドを含むscFV、Fab断片又は抗体。リガンドは特定のアミノ酸配列で表される相補性決定領域(CDRs)を含み標的分子に結合する。リガンドをコードする核酸、核酸を含むベクター、宿主細胞、アンチリガンドの免疫学的アッセイキット、及び抗体を含む薬学的組成物。 【選択図】図12
Abstract translation: 要解决的问题：提供与多发性硬化相关逆转录病毒（MSRV）相关疾病的诊断和治疗。解决方案：本发明涉及scFV，Fab片段或包含特异于MSRV包膜的配体（ENV）的抗体 ）蛋白，其是靶分子（抗配体）。 该配体与包含由特定氨基酸序列表示的互补决定区（CDR）的靶分子结合。 本发明还涉及含有编码配体的核酸，含有核酸的载体，宿主细胞，抗配体的免疫测定试剂盒和抗体的药物组合物。
-
公开(公告)号：JP3506252B2
公开(公告)日：2004-03-15
申请号：JP51497593
申请日：1993-02-19
Inventor： チャウ・ティリーサ・ピー , ハッドロック・ケネス・ジー , ファング・スティーヴン・ケイ・エイチ
IPC: G01N33/53 , C07K16/10 , C12P21/08 , G01N33/569 , G01N33/574 , G01N33/68
CPC classification number: C07K16/1036 , G01N33/56988 , G01N33/6854 , G01N2333/15 , Y10S435/81 , Y10S435/975
-
公开(公告)号：JPS59150340A
公开(公告)日：1984-08-28
申请号：JP2523383
申请日：1983-02-16
Applicant: Otsuka Pharmaceut Co Ltd
Inventor： SHIMIZU FUMIO , TACHIKAWA TETSUYA , IKEI NOBUHIRO , NODA ATSUYA , HASHIMURA ETSUROU , IMAGAWA KENICHI
IPC: G01N33/574 , A61K39/00 , C07K7/06 , C07K14/00 , C07K14/15 , C07K14/435 , C07K16/00 , C07K16/10
CPC classification number: C07K14/005 , C07K16/1036 , C12N2740/14022
Abstract: PURPOSE:To obtain a novel antibody which reacts specifically to an antigen related to a human T cell leukemia by using an immuno-antigen with a specified peptide as hapten employing a commercial amino acid. CONSTITUTION:In the production of an antibody, a specific amount of an immuno-antigen comprising a composite of a compound selected from peptide related to a human leukemia virus expressed by the formula (where, R represents hydrogen atom or H-Tyr) and a derivative thereof and a carrier is diluted with a saline solution to a proper concentration and mixed with a Freund's adjuvant to adjust a suspension. The suspension is injected subcutaneously into a mammal and thereafter, continuously dosed for 4-6 months to immunize. To sample the antibody, one-two weeks after the final dosage of said suspension, blood is sampled from the annimal immunized and following centrifugal separation, the secrum is separated. Thus, an antibody with a high titer and a high sensitivity can be obtained having an excellent specificity to ATLA, particularly p24.
Abstract translation: 目的：通过使用具有特定肽的免疫抗原作为使用商业氨基酸的半抗原，获得与人类T细胞白血病相关的抗原特异性反应的新型抗体。 构成：在抗体的制备中，特定量的免疫抗原，其包含选自与由式（其中，R表示氢原子或H-Tyr）表示的人白血病病毒有关的肽的化合物和 衍生物和载体用盐水溶液稀释至适当浓度并与弗氏佐剂混合以调节悬浮液。 将悬浮液皮下注射到哺乳动物中，然后连续给药4-6个月以免疫。 为了在所述悬浮液的最终剂量的一至两周后对抗体进行采样，从最近免疫的和随后的离心分离中取血，分离出secrum。 因此，可以获得具有高滴度和高灵敏度的抗体，其对ATLA具有优异的特异性，特别是p24。
-
公开(公告)号：US12060412B2
公开(公告)日：2024-08-13
申请号：US16087036
申请日：2016-10-27
Applicant: THE BROAD INSTITUTE, INC. , MASSACHUSETTS INSTITUTE OF TECHNOLOGY , PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Inventor： Aviv Regev , Feng Zhang , Naomi Habib , Yinqing Li , Matthias Heidenreich , Lukasz Swiech , Anindita Basu , David Weitz , Inbal Avraham Davidi
IPC: C07K16/10 , C12N15/10 , C12Q1/686 , C12Q1/6869
CPC classification number: C07K16/1036 , C12N15/1093 , C12N15/1096 , C12Q1/686 , C12Q1/6869 , C12Q2537/165 , C12Q2563/179 , C12Q2565/514 , C12Q2565/629 , C12Q1/6869 , C12Q2537/165 , C12Q2563/179 , C12Q2565/514 , C12Q2565/629
Abstract: Transcriptomes of individual neurons provide rich information about cell types and dynamic states. However, it is difficult to capture rare dynamic processes, such as adult neurogenesis, because isolation from dense adult tissue is challenging, and markers for each phase are limited. Here, Applicants developed Nuc-seq, Div-Seq, and Dronc-Seq. Div-seq combines Nuc-Seq, a scalable single nucleus RNA-Seq method, with EdU-mediated labeling of proliferating cells. Nuc-Seq can sensitively identify closely related cell types within the adult hippocampus. Div-Seq can track transcriptional dynamics of newborn neurons in an adult neurogenic region in the hippocampus. Dronc-Seq uses a microfluidic device to co-encapsulate individual nuclei in reverse emulsion aqueous droplets in an oil medium together with one uniquely barcoded mRNA-capture bead. Finally, Applicants found rare adult newborn GABAergic neurons in the spinal cord, a non-canonical neurogenic region. Taken together, Nuc-Seq, Div-Seq and Dronc-Seq allow for unbiased analysis of any complex tissue.
-
Patent Agency Ranking
公开(公告)号：US20180057569A1
公开(公告)日：2018-03-01
申请号：US15794541
申请日：2017-10-26
Applicant: GENEURO SA
Inventor： Corinne BERNARD , Alois Bernhardt LANG , Herve PERRON , Jean-Baptiste BERTRAND
CPC classification number: C07K16/1036 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92
Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
-
公开(公告)号：US09840550B2
公开(公告)日：2017-12-12
申请号：US14429199
申请日：2013-10-01
Applicant: GENEURO SA
Inventor： Hervé Perron , Reza Firouzi , Patrick Küry , Raphaël Faucard , Alexandra Madeira , Julie Joanou
IPC: A61K39/42 , A61K31/17 , A61K31/194 , C07K16/10 , A61K45/06 , A61K31/155 , A61K31/223 , A61K31/225 , A61K31/221 , A61K39/00
CPC classification number: C07K16/1036 , A61K31/155 , A61K31/17 , A61K31/194 , A61K31/221 , A61K31/223 , A61K31/225 , A61K39/42 , A61K45/06 , A61K2039/505 , A61K2300/00 , C07K2317/24 , C07K2317/565 , C07K2317/76
Abstract: The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
-
公开(公告)号：US09815888B2
公开(公告)日：2017-11-14
申请号：US15367864
申请日：2016-12-02
Applicant: GENEURO SA
Inventor： Corinne Bernard , Alois Bernhardt Lang , Herve Perron , Jean-Baptiste Bertrand
IPC: A61K39/395 , C07K16/10 , A61K39/00
CPC classification number: C07K16/1036 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92
Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
-
公开(公告)号：US20170107274A1
公开(公告)日：2017-04-20
申请号：US15367864
申请日：2016-12-02
Applicant: GENEURO SA
Inventor： Corinne BERNARD , Alois Bernhardt LANG , Herve PERRON , Jean-Baptiste BERTRAND
IPC: C07K16/10
CPC classification number: C07K16/1036 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92
Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.
-
公开(公告)号：US09243055B2
公开(公告)日：2016-01-26
申请号：US13846612
申请日：2013-03-18
Inventor： Feng Wang-Johanning
IPC: C07K16/10 , A61K39/00 , A61K47/48 , C07K16/30 , G01N33/574
CPC classification number: C07K16/1036 , A61K39/0011 , A61K47/6839 , A61K47/6855 , A61K47/6865 , A61K47/6869 , A61K2039/505 , C07K16/3015 , C07K16/3053 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2319/55 , C12N2740/10011 , G01N33/57407 , G01N33/57415 , G01N33/57434 , G01N33/57449 , G01N33/57484 , G01N33/57492
Abstract: Methods and compositions for cancer diagnostics and therapy are provided. More particular, methods and compositions for detecting, preventing, and treating HERV-K+ cancers are provided. One example of a method may involve a method for preventing or inhibiting cancer cell proliferation by administering to a subject a cancer cell proliferation blocking or reducing amount of a HERV-K env protein binding antibody.
Abstract translation: 提供了癌症诊断和治疗的方法和组合物。 提供了更具体的用于检测，预防和治疗HERV-K +癌症的方法和组合物。 方法的一个实例可以涉及通过向受试者施用癌细胞增殖阻断或减少HERV-K env蛋白结合抗体的量来预防或抑制癌细胞增殖的方法。
-
-
-
-
-
-
-
-
-
Search Results
286
records
(took 0.037 seconds)
